Advertisement

The highs and lows of cardiovascular disease prevention

      2017 saw the culmination of a number of trials evaluating novel approaches to prevention of atherosclerotic cardiovascular disease (ASCVD). Here we overview some of the highlights from the year.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N. Engl. J. Med. 2017; 376: 1713-1722
        • Roth E.M.
        A safety evaluation of evolocumab.
        Expet Opin. Drug Saf. 2018; 17: 99-106
        • Giugliano R.P.
        • Pedersen T.R.
        • Park J.G.
        • et al.
        Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
        Lancet. 2017; 390: 1962-1971
        • Sabatine M.S.
        • Leiter L.A.
        • Wiviott S.D.
        • et al.
        Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
        Lancet Diabetes Endocrinol. 2017; 5: 941-950
        • Giugliano R.P.
        • Keech A.
        • Murphy S.A.
        • et al.
        Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial.
        JAMA Cardiol. 2017; 2: 1385-1391
        • Bonaca M.P.
        • Nault P.
        • Giugliano R.P.
        • et al.
        Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease. Insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk).
        Circulation. 2017; ([Epub ahead of print])https://doi.org/10.1161/CIRCULATIONAHA.117.032235
        • Sabatine M.S.
        • De Ferrari G.M.
        • Giugliano R.P.
        • et al.
        Clinical benefit of evolocumab in patients with a history of MI: an analysis of FOURIER.
        in: American Heart Association Annual Scientific Sessions. Late-Breaking Science in Prevention. November 13, 2017
        • Ridker P.M.
        • Tardif J.C.
        • Amarenco P.
        • et al.
        Lipid reduction variability and antidrug-antibody formation with bococizumab.
        N. Engl. J. Med. 2017; 376: 1517-1526
        • Ridker P.M.
        • Revkin J.
        • Amarenco P.
        • et al.
        Cardiovascular efficacy and safety of bococizumab in high-risk patients.
        N. Engl. J. Med. 2017; 376: 1527-1539
      1. Ridker PM on behalf of the studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) investigators. Cardiovascular efficacy of PCSK9 inhibition among 1,578 patients with familial hypercholesterolemia: the SPIRE clinical trials FH analysis. Abstract M2006. AHA Scientific Sessions, Presented 13 November, 2017.

        • Landmesser U.
        • Chapman M.J.
        • Stock J.K.
        • et al.
        Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
        Eur. Heart J. 2017; 2017 ([Epub ahead of print])https://doi.org/10.1093/eurheartj/ehx549
        • Annemans L.
        • Packard C.J.
        • Briggs A.
        • Ray K.K.
        'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.
        Eur. Heart J. 2017; ([Epub ahead of print])https://doi.org/10.1093/eurheartj/ehx710
        • Nicholls S.J.
        • Puri R.
        • Anderson T.
        • et al.
        Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.
        J. Am. Med. Assoc. 2016; 316: 2373-2384
        • Liuzzo G.
        • Biasucci L.M.
        • Gallimore J.R.
        • et al.
        The prognostic value of C-reactive protein and serum amyloid A in severe unstable angina.
        N. Engl. J. Med. 1994; 331: 417-424
        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N. Engl. J. Med. 2017; 377: 1119-1131
        • Ridker P.M.
        • MacFadyen J.G.
        • Everett B.M.
        • et al.
        Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
        Lancet. 2017; ([Epub ahead of print])https://doi.org/10.1016/S0140-6736(17)32814-3
        • Ridker P.M.
        • MacFadyen J.G.
        • Thuren T.
        • et al.
        Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
        Lancet. 2017; 390: 1833-1842
        • Barter P.J.
        • Caulfield M.
        • Eriksson M.
        • et al.
        ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events.
        N. Engl. J. Med. 2007; 357: 2109-2122
        • Schwartz G.G.
        • Olsson A.G.
        • Abt M.
        • et al.
        Effects of dalcetrapib in patients with a recent acute coronary syndrome.
        N. Engl. J. Med. 2012; 367: 2089-2099
        • Lincoff A.M.
        • Nicholls S.J.
        • Riesmeyer J.S.
        • et al.
        Evacetrapib and cardiovascular outcomes in high-risk vascular disease.
        N. Engl. J. Med. 2017; 376: 1933-1942
        • Bowman L.
        • Hopewell J.C.
        • et al.
        • HPS3/TIMI55–REVEAL Collaborative Group
        Effects of anacetrapib in patients with atherosclerotic vascular disease.
        N. Engl. J. Med. 2017; 377: 1217-1227
        • Krishna R.
        • Gheyas F.
        • Liu Y.
        • et al.
        Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination.
        Clin. Pharmacol. Ther. 2017; 102: 832-840
        • Fernández-Friera L.
        • Peñalvo J.L.
        • Fernández-Ortiz A.
        • et al.
        Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) study.
        Circulation. 2015; 131: 2104-2113
        • Fernández-Friera L.
        • Fuster V.
        • López-Melgar B.
        • et al.
        Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors.
        J. Am. Coll. Cardiol. 2017; 70: 2979-2991
        • Pinkosky S.L.
        • Newton R.S.
        • Day E.A.
        • et al.
        Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
        Nat. Commun. 2016; 713457